本文選題：腦梗死 + 高同型半胱氨酸�。� 參考：《腦與神經(jīng)疾病雜志》2016年12期

【摘要】：目的觀察急性腦梗死(ACI)患者合并高同型半胱氨酸血癥(Hhcy)阿司匹林抵抗(AR)發(fā)生情況及相關(guān)因素。方法 2014年9月—2015年12月本院神經(jīng)內(nèi)科收治的急性腦梗死(ACI)患者146例為研究對(duì)象,根據(jù)同型半胱氨酸(Hcy)水平分為兩組:Hhcy組(觀察組)78例,非Hhcy組(對(duì)照組)68例,入院后兩組均服阿司匹林100mg.d~(-1),連服1個(gè)月后,檢測(cè)血常規(guī)、凝血常規(guī)和血小板聚集率,進(jìn)行阿司匹林的療效評(píng)價(jià),AR定義為花生四烯酸誘導(dǎo)的血小板聚集率≥20%。結(jié)果 Hhcy組AR發(fā)生率為21.8%,明顯高于非Hhcy組8.8%,兩者相比差異有統(tǒng)計(jì)學(xué)意義(P0.05)。Logistic回歸分析顯示,Hhcy是發(fā)生AR的獨(dú)立危險(xiǎn)因素(β=-0.58,P0.01)。結(jié)論 ACI患者合并Hhcy的AR發(fā)生率明顯增加,Hhcy是ACI患者發(fā)生AR的重要危險(xiǎn)因素。臨床工作中應(yīng)給予充分重視,積極檢測(cè)血清Hcy水平,積極監(jiān)測(cè)血小板聚集率,預(yù)測(cè)AR,避免或延緩血栓性疾病的發(fā)生。
[Abstract]:Objective to observe the incidence and related factors of aspirin resistance (ARL) in patients with acute cerebral infarction (ACI) complicated with hyperhomocysteinemia. Methods from September 2014 to December 2015, 146 patients with acute cerebral infarction (ACI) treated in neurology department of our hospital were divided into two groups according to the level of homocysteine Hcycy (observation group 78 cases, non-HHcy group 68 cases, control group 68 cases). After admission, both groups were given 100 mg 路d ~ (-1) of aspirin. After taking aspirin for one month, blood routine examination, blood coagulation test and platelet aggregation rate were measured. The evaluation of the curative effect of aspirin was as follows: arachidonic acid-induced platelet aggregation rate 鈮，

本文編號(hào)：2031712